Initial clinical experience with regadenoson, a novel selective A _2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging

Keyphrases

• Clinical Experience 100%
• Single-photon Emission Computed Tomography (SPECT) 100%
• Pharmacological Assays 100%
• Computed Tomography Perfusion 100%
• Regadenoson 100%
• Adenosine 57%
• Hypoperfusion 28%
• Ischemia 14%
• Radiopharmaceuticals 14%
• Dyspnea 14%
• Continuous Infusion 14%
• Pharmacologic 14%
• Tolerability 14%
• Imaging Studies 14%
• 17-segment Model 14%
• Reduced Side Effects 14%
• Adenosine A2A Receptor Antagonist 14%
• Adenosine Agonist 14%
• Non-selective 14%
• Undesirable Side Effects 14%
• Bolus Dose 14%
• Ann Arbor 14%
• Intravenous Bolus 14%
• Computed Tomography Images 14%
• Central Laboratory 14%
• Phase III Clinical Trial 14%
• University of Michigan 14%
• High-degree Atrioventricular Block 14%
• Michigan 14%
• Pharmacological Stress 14%
• Stress Agents 14%
• Single-photon Emission Computed Tomography Imaging 14%
• Bronchospasm 14%
• Dipyridamole 14%
• Open-label Trial 14%
• Bolus Administration 14%
• Self-limiting 14%
• Myocardial Hypoperfusion 14%
• Chest Discomfort 14%

Medicine and Dentistry

• Single-Photon Emission Computed Tomography 100%
• Myocardial Perfusion Imaging 100%
• Regadenoson 100%
• Adenosine 57%
• Side Effect 42%
• Adenosine Receptor Agonist 28%
• Clinical Trial 14%
• Scintigraphy 14%
• Ischemia 14%
• Dyspnea 14%
• Thorax Pain 14%
• Continuous Infusion 14%
• Open-Label Trial 14%
• Bronchospasm 14%
• Atrioventricular Block 14%
• Radiopharmaceutical 14%
• Dipyridamole 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Regadenoson 100%
• Adenosine 57%
• Side Effect 42%
• Adenosine Receptor Stimulating Agent 28%
• Clinical Trial 14%
• Dyspnea 14%
• Thorax Pain 14%
• Tolerability 14%
• Ischemia 14%
• Open-Label Trial 14%
• Atrioventricular Block 14%
• Dipyridamole 14%
• Bronchospasm 14%